Elevation Oncology (ELEV) News Today

Elevation Oncology, Inc. (NASDAQ:ELEV - Free Report) - Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for Elevation Oncology in a report released on Wednesday, July 24th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.80) per share

JMP Securities reiterated a "market outperform" rating and set a $7.00 price objective on shares of Elevation Oncology in a research note on Friday.

Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) has been given a consensus recommendation of "Buy" by the six research firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objecti

Stephens initiated coverage on shares of Elevation Oncology in a research note on Tuesday. They issued an "overweight" rating and a $8.00 target price on the stock.

Wedbush reissued an "outperform" rating and issued a $8.00 price target on shares of Elevation Oncology in a research note on Friday.

Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 5,010,000 shares, a growth of 8.2% from the March 15th total of 4,630,000 shares. Currently, 12.6% of the shares of the company are sold short. Based on an average daily volume of 3,060,000 shares, the days-to-cover ratio is currently 1.6 days.

HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Elevation Oncology in a research report on Tuesday.

Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 4,630,000 shares, a growth of 28.3% from the February 29th total of 3,610,000 shares. Based on an average daily volume of 2,940,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 11.6% of the company's stock are short sold.

Elevation Oncology, Inc. (NASDAQ:ELEV - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2025 EPS estimates for shares of Elevation Oncology in a note issued to investors on Thursday, March 7th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earn

Armistice Capital LLC lowered its stake in shares of Elevation Oncology, Inc. (NASDAQ:ELEV - Free Report) by 68.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 750,000 shares of the company's stock

Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 4,010,000 shares, an increase of 13.9% from the January 31st total of 3,520,000 shares. Based on an average daily trading volume, of 2,620,000 shares, the short-interest ratio is presently 1.5 days. Approximately 11.6% of the shares of the stock are short sold.

JMP Securities began coverage on shares of Elevation Oncology in a research report on Friday. They set an "outperform" rating and a $7.00 price objective on the stock.